Yahoo Finance 
$517.2 Million Worldwide Dried Blood Spot Collection Cards Industry to 2030 - Featuring Qiagen, PerkinElmer, Roche and Pall Among Others
Global Dried Blood Spot Collection Cards Market
Dublin, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The "Dried Blood Spot Collection Cards Market Size, Share & Trends Analysis Report by Application (New Born Screening, Infectious Disease Testing, Forensics), by Card Type, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global dried blood spot collection cards market size is expected to reach USD 517.2 million by 2030, expanding at a CAGR of 4.2% from 2022 to 2030. Dried blood spot (DBS) collection cards are used to diagnose infectious diseases, particularly in resource-constrained areas, or to screen newborns for inherited metabolic problems, with a range of novel and innovative DBS uses only lately emerging.
Growing research studies for DBS testing and its advantages for diagnostic purposes are expected to fuel the market growth during the forecast period. In addition, the WHO recently recommended dried blood spot collection cards for diagnosis of HIV and hepatitis B & C due to the benefits of DBS in collecting blood and transport.
Moreover, dried blood spot collection cards have been used in a variety of toxicology applications, including toxicokinetics, epidemiological, environmental, and forensic toxicology. Dried blood spot collection cards are anticipated to be used as a sample preparation approach in forensic toxicology, and they can cost-effectively retain evidence for closed cases. Screening procedures as well as follow-up of markers of clinical or forensic interest are further toxicological applications where these cards may be progressively utilized.
Developing economies in Africa and Asia have the highest prevalence of rabies. The detection and surveillance of such diseases are hampered by the absence of clinical laboratories. Through dried blood spot collection cards, rabies can be diagnosed with limited resources. As per the data published by the Australian Trade and Investment Commission, Australia has become home to a thriving network of more than 470 biotechnology companies. A high number of established biotechnology and pharmaceutical players and extensive R&D initiatives being undertaken by them are expected to create a high need for DBS testing for therapeutic drug monitoring applications.
Various international organizations such as the U.S. Food and Drug Administration and the World Health Organization acknowledge the role of DBS cards in this pandemic. For instance, In June 2021, Symbiotic, Inc. was granted EUA by the FDA for a COVID-19 self-collect antibody test. This test can be conducted using ELISA with DBS for detecting COVID-19 antibodies in individuals aged 18 years and older, with collecting the sample in children aged 5 years and older by an adult.
The increase in the adoption of dried blood spot collection cards for therapeutic drug monitoring is a major factor expected to boost market growth in the near future. For instance, in July 2022, a study was conducted by researchers from the University of Washington and Med Biotech Laboratories to assess the feasibility of at-home dried blood spot collection along with PCR as a technique for malaria research. The study is anticipated to impact the therapeutic drug and vaccine studies for malaria. Researchers concluded that at-home dried blood spot collection cards for PCR are acceptable, robust, and feasible techniques.
On the other hand, it has been observed that dried blood spot collection cards are susceptible to cross-contamination or contamination by users, the environment, the equipment, and other collection cards during sample processing. The majority of these concerns can be mitigated by proper care and handling. Prolonged air drying of the conventional dried blood spot collection cards and contamination between samples during blood collection are some major causes of a high proportion of reactive samples.
Dried Blood Spot Collection Cards Market Report Highlights
By application, the New Born Screening (NBS) segment accounted for the largest revenue in 2021. An increase in research activities to enhance newborn screening is a major factor expected to fuel market growth
By card type, the Whatman 903 segment dominated the market in 2021 and is expected to register the fastest growth rate from 2022 to 2030. At present, the Whatman paper is widely utilized in the testing of viral infections and the monitoring of therapeutic drugs
North America dominated the market in 2021. This can be attributed to high healthcare expenditure, the presence of well-established healthcare infrastructure, and the high adoption of advanced dried blood spot collection cards in the U.S.
The Asia Pacific region is anticipated to witness lucrative growth over the forecast period as a result of an increasing number of leading players in the region
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Dried Blood Spot Collection Cards Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.2.1 User Perspective Analysis
3.2.1.1 Consumer Behavior Analysis
3.3 Regulatory Framework
3.3.1 Reimbursement Framework
3.3.2 Standards And Compliances
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Use Of Dbs Cards In Newborn Screening
3.4.1.2 Increasing Use Of Dbs Cards In Diagnostic Testing
3.4.1.3 Rise Of Forensic Toxicology Applications
3.4.2 Market Restraint Analysis
3.4.2.1 Contamination Caused in DBS Collection Cards
3.5 Dried Blood Spot Collection Cards Market Analysis Tools
3.5.1 Industry Analysis - Porter's
3.5.2 Pestel Analysis
3.5.3 Major Deals And Strategic Alliances Analysis
3.5.4 Covid-19 Impact Analysis
Chapter 4 Dried Blood Spot Collection Cards Market: Application Estimates and Trend Analysis
4.1 Global Dried Blood Spot Collection Cards Market: by Application Movement Analysis
4.2 New Born Screening
4.2.1 New Born Screening Market, 2018 To 2030 (USD Million)
4.3 Infectious Disease Testing
4.3.1 Infectious Disease Testing Market, 2018 To 2030 (USD Million)
4.4 Therapeutic Drug Monitoring
4.4.1 Therapeutic Drug Monitoring Market, 2018 To 2030 (USD Million)
4.5 Forensics
4.5.1 Forensics Market, 2018 To 2030 (USD Million)
4.6 Cro/Research
4.6.1 Cro/Research Market, 2018 To 2030 (USD Million)
4.7 Other Applications
4.7.1 Other Applications Market, 2018 To 2030 (USD Million)
Chapter 5 Dried Blood Spot Collection Cards Market: Card Type Estimates and Trend Analysis
5.1 Global Dried Blood Spot Collection Cards Market: Card Type Movement Analysis
5.2 whatman 903
5.2.1 Whatman 903 Market, 2018 To 2030 (USD Million)
5.3 Ahlstrom 225
5.3.1 Ahlstrom 225 Market, 2018 To 2030 (USD Million)
5.4 FTA
5.4.1 FTA Market, 2018 To 2030 (USD Million)
5.5 Other Card Type
5.5.1 Other Card Type Market, 2018 To 2030 (USD Million)
Chapter 6 Dried Blood Spot Collection Cards Market: Regional Estimates & Trend Analysis
Chapter 7 Company Landscape
7.1 Public Companies
7.1.1 Company Market Position Analysis
7.1.2 Competitive Dashboard Analysis
7.1.3 Strategic Framework
7.2 Private Companies
7.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
7.2.2 Regional Network Map
7.3 Company Profiles
7.3.1 QIAGEN
7.3.1.1 Company overview
7.3.1.2 Financial Performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 PERKINELMER
7.3.2.1 Company overview
7.3.2.2 Financial Performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 ROCHE
7.3.3.1 Company overview
7.3.3.2 Financial Performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 SHIMAZDU
7.3.4.1 Company overview
7.3.4.2 Financial Performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 AHLSTROM-MUNKSJO
7.3.5.1 Company overview
7.3.5.2 Financial Performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 PALL CORPORATION
7.3.6.1 Company overview
7.3.6.2 Financial Performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 EASTERN BUSINESS FORMS, INC.
7.3.7.1 Company overview
7.3.7.2 Financial Performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 ARCHIMEDLIFE
7.3.8.1 Company overview
7.3.8.2 Financial Performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
7.3.9 CENTOGENE AG
7.3.9.1 Company overview
7.3.9.2 Financial Performance
7.3.9.3 Product benchmarking
7.3.9.4 Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/78kzz
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
